Suraksha Diagnostic Reports Strong Q3FY26 Growth with 30% Revenue Increase
Suraksha Diagnostic Limited delivered impressive Q3FY26 performance with consolidated revenue growing 30.50% to ₹776.87 million and test volumes increasing 30.70% to 2.06 million. The company maintained strong operational metrics with improved tests per patient ratio and published regulatory compliance filings in newspapers on February 6, 2026.
*this image is generated using AI for illustrative purposes only.
Suraksha Diagnostic Limited announced strong financial results for the quarter ended December 31, 2025, demonstrating robust growth across key operational and financial metrics. The largest integrated diagnostic chain in East India reported significant expansion in both revenue and test volumes, reflecting the company's successful network expansion strategy.
Financial Performance Highlights
The company delivered impressive financial results for Q3FY26, with consolidated revenue reaching ₹776.87 million compared to ₹595.13 million in the corresponding quarter of the previous year. The standalone total income reached ₹765.68 million compared to ₹595.45 million in Q3FY25, representing a substantial 28.60% year-on-year growth.
| Financial Metric: | Q3 FY26 | Q3 FY25 | Growth (%) |
|---|---|---|---|
| Consolidated Revenue: | ₹776.87 million | ₹595.13 million | +30.50% |
| Standalone Total Income: | ₹765.68 million | ₹595.45 million | +28.60% |
| Consolidated Net Profit: | ₹72.41 million | ₹59.85 million | +21.00% |
| Standalone PAT: | ₹81.41 million | ₹63.57 million | +28.00% |
| EBITDA: | ₹232.00 million | ₹183.00 million | +26.80% |
| EBITDA Margin: | 29.82% | 30.68% | -86 bps |
| EPS: | ₹1.56 | ₹1.22 | +27.87% |
EBITDA grew by 26.80% to ₹232.00 million, though the EBITDA margin compressed to 29.82% from 30.68% in the previous year. The consolidated net profit increased to ₹72.41 million from ₹59.85 million, while standalone profit after tax reached ₹81.41 million.
Operational Excellence and Volume Growth
The company's operational metrics demonstrated strong performance across all key parameters. Total tests conducted reached 2.06 million, marking a significant 30.70% increase from 1.57 million tests in Q3FY25. The patient base expanded to 0.36 million, representing a 23.00% growth from 0.29 million patients in the corresponding previous quarter.
| Operational Metric: | Q3 FY26 | Q3 FY25 | Growth (%) |
|---|---|---|---|
| Total Tests: | 2.06 million | 1.57 million | +30.70% |
| Total Patients: | 0.36 million | 0.29 million | +23.00% |
| Tests per Patient: | 5.77 | 5.43 | +6.20% |
| Average Revenue per Test: | ₹378 | ₹378 | -0.10% |
| Average Revenue per Patient: | ₹2,181 | ₹2,054 | +6.10% |
The tests per patient metric improved to 5.77 from 5.43, indicating enhanced service utilization. Average revenue per patient increased by 6.10% to ₹2,181, while average revenue per test remained stable at ₹378.
Nine-Month Performance Overview
For the nine-month period ended December 31, 2025, Suraksha Diagnostic maintained strong growth momentum with standalone total income of ₹2,251.73 million, up 19.50% from ₹1,883.91 million in the corresponding period of the previous year. Consolidated total income reached ₹2,313.81 million with a 21.80% growth rate, while profit after tax stood at ₹252.43 million, representing a 6.00% increase.
| Nine-Month Metrics: | 9M FY26 | 9M FY25 | Growth (%) |
|---|---|---|---|
| Standalone Total Income: | ₹2,251.73 million | ₹1,883.91 million | +19.50% |
| Consolidated Total Income: | ₹2,313.81 million | ₹1,900.27 million | +21.80% |
| Standalone PAT: | ₹273.53 million | ₹254.33 million | +7.55% |
| Consolidated PAT: | ₹252.43 million | ₹238.07 million | +6.00% |
Regulatory Compliance and Publication
The unaudited financial results have been prepared in accordance with Indian Accounting Standards and reviewed by MSKA & Associates LLP, Chartered Accountants. The statutory auditors have issued an unmodified conclusion on both standalone and consolidated financial results. The results were reviewed by the Audit Committee and approved by the Board of Directors on February 5, 2026.
| Regulatory Details: | Information |
|---|---|
| BSE Scrip Code: | 544293 |
| NSE Symbol: | SURAKSHA |
| Publication Date: | February 6, 2026 |
| Newspapers: | Business Standard (English), Aajkaal (Bengali) |
| Website: | www.surakshanet.com |
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its unaudited financial results in Business Standard and Aajkaal newspapers on February 6, 2026.
Strategic Expansion and Market Position
According to Joint Managing Director & CEO Mrs. Ritu Mittal, the company's growth strategy focuses on network expansion and operational excellence. During the nine-month period, Suraksha Diagnostic added 12 fully operational centres with 6 additional centres under development. The company has also launched Suraksha Sutra, its genomics and molecular vertical, establishing a first-mover advantage in the high-value genomics segment in Eastern India.
The company operates as the largest integrated diagnostic chain with presence across West Bengal, Bihar, Assam, and Meghalaya. Its central reference laboratory holds accreditation from the College of American Pathologists, while four laboratories maintain NABL accreditation and three advanced diagnostic centres are NABH accredited.
